New kid on the block
This article was originally published in The Tan Sheet
Dynova Laboratories enters the supplement market with the acquisition of SiCaps Industries and its capsaicin-based Sinus Buster brand products. Parsippany, N.J.-based Dynova, backed by the private equity fund Aisling Capital, looks to provide clinical, marketing, packaging and sales support to "novel" dietary supplement products and ingredients with "unique delivery" and "compelling claims," according to Dynova's Web site. The firm led by former Novartis OTC business executives Lynne Millheiser-Swanbeck and Jeff Vernimb, and by Jennifer Cooper, formerly with Twin Laboratories and Solgar...
You may also be interested in...
In this new roundup feature focusing on the most notable developments in digital health, we pick the key news from the year so far.
US Regulatory Roundup, February 2021: QA/RA Predictions, FDA Warning Letter Stats, PMA Case Study, And More
Quality and regulatory predictions for 2021, a count of 2020 US FDA enforcement missives, a premarket approval case study for a novel prosthetic, and more topped our list of most-read Medtech Insight articles in February.
Locke Lord senior counsel Sharon Blinkoff shares perspective from her experience defending smaller cosmetics companies against US class action plaintiff demands and litigation.